Skip to main content
EJNMMI Research
Fig. 2 | EJNMMI Research

Fig. 2

From: The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor

Fig. 2

A single dose of AZD8186 (50 mg/kg) reduces 18F-FDG uptake 2 h after dosing in the PTEN null 786-0 and U87-MG xenograft models but not the BT474C PI3Kα model. a MaxSUV tumour 18F-FDG uptake following AZD8186 dosing (mean ± SEM). b Representative images from each cell line. 786-0: vehicle n = 10; AZD8186 n = 11. U87-MG: vehicle n = 8; AZD8186 n = 9. BT474C: vehicle n = 7; AZD87186 n = 8. *p < 0.05 unpaired t test

Back to article page